American Heart Journal
Volume 144, Issue 6 , Pages 941-947 , December 2002

The relevance of subgroup-specific treatment effects: The Studies Of Left Ventricular Dysfunction (SOLVD) revisited

Received 5 September 2001 ,Accepted 10 April 2002.

References 

  1. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ. 1995;311:1356–1359
  2. Lubsen LJ, Tijssen JG. Large trials with simple protocols: indications and contraindications. Control Clin Trials. 1989;10:151S–160S
  3. Rothwell PM. Can overall results of clinical trials be applied to all patients?. Lancet. 1995;345:1616–1619
  4. Rothwell PM. What do the overall results of clinical trials and meta-analyses tell us about the efficacy of treatments?. J Nephrol. 1997;10:5–6
  5. Parker AB, Naylor CD. Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. Am Heart J. 2000;130:952–961
  6. The SOLVD Investigators . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302
  7. The SOLVD Investigators . Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–691
  8. Breslow NE. Statistics in epidemiology: the case-control study. J Am Stat Assoc. 1996;91:14–28
  9. Miettinen OS. Stratification by multivariate confounder score. Am J Epidemiol. 1976;104:609–620
  10. Hosmer DW, Lemeshow S. Applied logistic regression. In: New York: : Wiley; 1989;p. 135–175
  11. Glantz SA, Slinker BK. Primer of applied regression and analysis of variance. In: New York: McGraw-Hill;; 1990;p. 531
  12. Hosmer DW, Lemeshow S. Applied logistic regression. In: New York: : Wiley; 1989;p. 131
  13. Harjai KJ, Nunez E, Turgut T, et al.  The independent effects of left ventricular ejection fraction on short-term outcomes and resource utilization following hospitalization for heart failure. Clin Cardiol. 1999;22:184–190
  14. Nicod P, Gilpin E, Dittrich H, et al.  Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction. Am J Cardiol. 1988;61:1165–1171
  15. Pernenkil R, Vinson JM, Shah AS, et al.  Course and prognosis in patients ≥70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol. 1997;79:216–219
  16. Savage MP, Krolewski AS, Kenien GG, et al.  Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol. 1988;62:665–669
  17. Zaret BL, Wackers FJ, Terrin ML, et al.  Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. J Am Coll Cardiol. 1995;26:73–79
  18. Carson P, Johnson G, Fletcher R, et al.  Mild systolic dysfunction in heart failure (left ventricular ejection fraction > 35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). J Am Coll Cardiol. 1996;27:642–649
  19. Cintron G, Johnson G, Francis G, et al.  Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI17–VI23
  20. Grondin P, Donzaeau-Gouge GP, Bical O, et al.  Royal College Lecture, 1976: preoperative left ventricular ejection fraction and survival after coronary artery surgery. Can J Surg. 1976;19:487–493
  21. Melchior T, Gadsboll N, Hildebrandt P, et al.  Clinical characteristics, left and right ventricular ejection fraction, and long-term prognosis in patients with non-insulin-dependent diabetes surviving an acute myocardial infarction. Diabet Med. 1996;13:450–456
  22. Shindler DM, Kostis JB, Yusuf S, et al.  Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996;77:1017–1020
  23. Al-Khadra AS, Salem DN, Rand WM, et al.  Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419–425
  24. The Digitalis Investigation Group . The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533
  25. Altman DG. Within trial variation—a false trail?. J Clin Epidemiol. 1998;51:301–303
  26. Bulpitt CJ. Subgroup analysis. Lancet. 1988;2:31–34
  27. Byar DP. Assessing apparent treatment-covariate interactions in randomized clinical trials. Stat Med. 1985;4:255–263
  28. Buyse ME. Analysis of clinical trial outcomes: some comments on subgroup analyses. Control Clin Trials. 1989;10:187S–194S
  29. Collins R, Gray R, Godwin J, et al.  Avoidance of large biases and large random errors in the assessment of moderate treatment effects: The need for systematic overviews. Stat Med. 1987;6:245–250
  30. Feinstein AR. The problem of cogent subgroups: a clinicostatistical tragedy. J Clin Epidemiol. 1998;51:297–299
  31. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics. 1985;41:361–372
  32. Gheorghiade M, Schultz L, Tilley B, et al.  Subgroup analysis of clinical trials. Am J Cardiol. 1991;67:330–332
  33. Horwitz RI, Singer BH, Makuch RW, et al.  Can treatment that is helpful on average be harmful to some patients? a study of the conflicting information needs of clinical inquiry and drug regulation. J Clin Epidemiol. 1996;49:395–400
  34. Horwitz RI, Singer BH, Makuch RW, et al.  On reaching the tunnel at the end of the light. J Clin Epidemiol. 1997;50:753–755
  35. Horwitz RI, Singer BH, Makuch RW, et al.  Clinical versus statistical considerations in the design and analysis of clinical research. J Clin Epidemiol. 1998;4:305–307
  36. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116:78–84
  37. Peto R. Statistical aspects of cancer trials. In: London: : Chapman & Hall; 1982;p. 867–871
  38. Rockette HE, Caplan RJ. Strategies for subgroup analysis in clinical trials: recent results. Cancer Res. 1988;111:49–54
  39. Schneider B. Analysis of clinical trial outcomes: alternative approaches to subgroup analysis. Control Clin Trials. 1989;10:176S–186S
  40. Senn S, Harrell F. On wisdom after the event. J Clin Epidemiol. 1997;50:749–751
  41. Simon R. Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol. 1982;14:473–482
  42. Stallones RA. The use and abuse of subgroup analysis in epidemiological research. Prev Med. 1987;16:183–194
  43. Yusuf S, Wittes J, Probstfield J, et al.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93–98
  44. Yusuf S, Sleight P, Pogue J, et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  45. Packer M, O'Connor CM, Ghali JK, et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107–1114
  46. Praise-2. Prospective randomized amlodipine survival evaluation-2. Presented at: Proceedings of the 49th American College of Cardiology Meeting; March 12-15, 2000; Anaheim, Calif.

☆ Reprint requests: Andrea B. Parker, MSc, Cardiac Research Inc, 15 Oakley Pl, Toronto, Ontario, M2P 2G3 Canada.

☆☆ E-mail: abp.care@sympatico.ca

PII: S0002-8703(02)00218-1

doi: 10.1067/mhj.2002.126446

American Heart Journal
Volume 144, Issue 6 , Pages 941-947 , December 2002

Article Tools